The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

IL-17A inhibitors such as Novartis’ Cosentyx (secukinumab) and Eli Lilly’s Taltz (ixekizumab ... So far Xeljanz is approved for psoriatic arthritis only, as it was turned down by the ...

Cosentyx has since been joined by other IL-17 inhibitors including Eli Lilly's Taltz (ixekizumab ... approved in follow-up indications psoriatic arthritis and ankylosing spondylitis.

Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.

Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...

Tilt is a new makeup brand with products designed to make beauty accessible to everyone. It’s the first beauty brand and ...

Cosentyx (secukinumab) may be safe to use while pregnant or breastfeeding. Before starting treatment, you and your doctor can discuss the risks and benefits of Cosentyx treatment during pregnancy ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.